Therapeutic use of hematopoietic mesenchymal stem cells in osteoarthritis: a meta-analysis study

Posted on by

Muthanna Medical Journal

Volume 10, Issue 2,  2023 Page 173-188
http://dx.doi.org/10.52113/1/1/2023-173-188

Nasser Ghaly Yousif 1, Pingan Liu 2, Fadhil G. Al-amran3, Douglas L Hainz 4, Ahmed N. Altimimi 5

Correspondence author: yousif_ghaly@mu.edu.iq
1 Department of Medicine, Medical College, Al Muthanna University, Iraq.
2 Department of Reproductive Immunology, School of Medicine, China.
3 Department of Surgery, Medical College, Kufa University, Iraq.
4 Department of Immunology, Medical School, Australian National University, Australia.
5 Department of Laboratories, MOH, Iraq.
Received 11 May 2023; revised 21 June 2023; accepted 28 July 2023, available online 30 August 2023.
Copyright © 2023 Yousif NG et al. This is article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Abstract

Millions of people worldwide suffer from osteoarthritis, which is a major health problem. The accessible medicines are used in changing the side effects of osteoarthritis however missing illness alterations, not with-standing drug after-effects, and care expenses without adequacy of side effects help. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We look for relevant articles in all articles published between December 30, 2007, and December 30, 2022, in the Cochrane Library, PubMed, Embase, Wanfang Database, CNKI, and Web of Science databases. With an average follow-up of 18.33 months, this study included 364 patients with knee joint osteoarthritis from 12 completely published articles. Data from seven studies using the Visual Analog Scale (VAS) score. In Bone Marrow Mesenchymal Stem Cells (BM-MSCs), the baseline score on the Visual Analogue Scale decreased. These results suggested that there was no significant relationship between the BM-MSCs at three months (Weighted Mean Difference (WMD) =  1.07, 95% CI: − 2.44, − 0.39, p= 0.074); and the greatest decrease in VAS score compared to the control at 18.33 months, WMD =  6.04, 95 percent CI: − 10.34, − 0.38, p = 0.017. In clinical applications, intra-articular injection of BM-MSCs has advantages for treating OA because it reduces pain index, improves knee movement, and increases cartilage volume.

Keywords: BM-MSCs, Osteoarthritis, PRISMA